Castle Biosciences
CSTL
135 hedge funds and large institutions have $391M invested in Castle Biosciences in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 41 reducing their positions, and 16 closing their positions.
122% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $457K
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
27% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 41
23% more capital invested
Capital invested by funds: $317M → $391M (+$74.4M)
4% more funds holding
Funds holding: 130 → 135 (+5)
0.29% more ownership
Funds ownership: 86.07% → 86.35% (+0.29%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$16.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$8.08M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.06M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.96M |
| 5 |
Walleye Capital
New York
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$7.7M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$6.61M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$5.36M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.2M |
| 5 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$3.5M |
CSTL Hedge Fund Activity: Q3 2023 in Review
135 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Castle Biosciences (CSTL) for Q3 2023, worth a combined $391M — up 23% from $317M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CSTL positions and 16 closed out — a net gain of 6 holders — while 52 added to existing stakes and 41 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $16.6M. The largest seller was Millennium Management, cutting an estimated $7.7M.
- 135 institutional investors held Castle Biosciences (CSTL) as of Q3 2023, up from 130 in Q2 2023.
- Funds reported $391M of Castle Biosciences stock for Q3 2023, up 23% quarter-over-quarter.
- 22 funds opened new Castle Biosciences positions in Q3 2023 and 16 closed out, a net change of +6 holders.
- The largest Castle Biosciences buyer in Q3 2023 was Deerfield Management, an estimated $16.6M added.
- The largest Castle Biosciences seller in Q3 2023 was Millennium Management, an estimated $7.7M sold.
Based on aggregated 13F filings for Q3 2023.